Cross-reactivity of rabbit anti-bovine thrombin IgGs with human α-thrombin and a recombinant version of human thrombin (Recothrom)

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 3, 2010, Pages 273-280

  Zhu, He ^a   Hoppensteadt, Debra ^a   Cunanan, Josephine ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine thrombin; Human thrombin; Immunoglobulin G; Topical hemostatic agents; Western blot

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 5; HUMAN RECOMBINANT THROMBIN; IMMUNOGLOBULIN G; RECOTHROM; THROMBIN; THROMBIN 4A; THROMBIN 4B; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CROSS REACTION; DRUG SAFETY; NONHUMAN; PRIORITY JOURNAL; RABBIT; WESTERN BLOTTING;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; BLOTTING, WESTERN; CATTLE; CROSS REACTIONS; HEMOSTATICS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; RABBITS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; THROMBIN;

EID: 77953646230     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610363587     Document Type: Article

References (26)

1. Schoenecker JG, Hauck RK, Mercer MC, Parker W., Lawson JH Exposure to topical bovine thrombin during surgery elicits a response against the xenogenic carbohydrate galactose alpha1-3galactose. J Clin Immunol. 2000 ; 20 (6). 434-444.
2. Lawson JH The clinical use and immunologic impact of thrombin in surgery. Semin Thromb hemost. 2006 ; 32 (S1). 98-110.
3. Terrab A., Pawlak D., Spaay P., Hoppensteadt D., Fareed J. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost. 2008 ; 14 (2). 135-140.
4. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001 ; 58 (6). 710-719.
5. Rapaport SI, Zivelin A., Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992 ; 97 (1). 84-91.
6. Cmolik BL, Spero JA, Magovern GJ, Clark RE Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac cardiovasc Surg. 1993 ; 105 (2). 222-228.
7. Chouhan VD, De la cadena RA, Nagaswami C., Weisel JW, Kajani M., Rao AK Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V after exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost. 1997 ; 77 (2). 343-349.
8. Winterbottom N., Kuo JM, Nguyen K., et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Applied Res. 2002 ; 2: 1-11.
9. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994 ; 45 (2). 128-135.
10. Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990 ; 76 (10). 2011-2016.
11. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relative pure bovine thrombin. Ann Thorac Surg. 2005 ; 79 (3). 1037-1038.
12. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001 ; 233 (1). 88-96.
13. Sands JJ, Nudo SA, Ashford RG, Moore KD, Ortel TL Antibodies to topical bovine thrombin correlate with access thrombosis. Am J kidney Dis. 2000 ; 35 (5). 796-801.
14. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004 ; 18 (3). 349-351.
15. Savage WJ, Kickler TS, Takemoto CM Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer. 2007 ; 49 (7). 1025-1029.
16. Streiff MB, Ness PM Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002 ; 42 (1). 18-26.
17. Heffernan JK, Ponce RA, Zuckerman LA, et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol. 2007 ; 47 (1). 48-58.
18. Chapman WC, Lockstadt H., Singla N., Kafie FE, Lawson JH Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost. 2006 ; 4 (9). 2083-2085.
19. Chapman WC, Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ; 205 (2). 256-265.
20. Weaver F., Lew W., Granke K., et al. Study Investigators. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg. 2008 ; 47 (6). 1266-1273.
21. Greenhalgh DG, Gamelli RL, Collins J., et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res. 2009 ; 30 (3). 371-379.
22. Singla NK, Ballard JL, Moneta G., Randleman CD Jr, Renkens KL, Alexander WA A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg. 2009 ; 209 (1). 68-74.
23. Sandermann H. Jr, Stromiger JL Purification and properties of C 55-isoprenoid alcohol phosphokinase from staphylococcus aureus. J. Biol. Chem. 1972 ; 247 (16). 5123-5131.
24. Zhu H., Hoppensteadt D., Cunanan J., et al. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostaic application. Clin Appl Thromb Hemost. 2008 ; 15 (1). 32-40.
25. Zhu H., Hoppensteadt D., Adiguzel C., Bick RL, Fareed J. Comparison of immunogenic potentials of bovine thrombin preparations. Clin Appl Thromb Hemost. 2008 ; 15 (1). 41-49.
26. RecothromTM [Package insert]. Seattle, WA: Zymogenetics ; 2008.